亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药

休市中 06-12 16:08:21

34.900

+1.320

+3.93%

最高35.400	最低33.040	成交量287.60万
今开34.160	昨收33.580	日振幅7.03%
总市值130.53亿	流通市值130.53亿	总股本3.74亿
成交额9,887万	换手率0.77%	流通股本3.74亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药","latestPrice":34.9,"timestamp":1781251701009,"preClose":33.58,"halted":0,"volume":2875977,"delay":0,"changeRate":0.03930911256700418,"floatShares":374000000,"shares":374000000,"eps":-4.043302354738863,"marketStatus":"休市中","change":1.32,"latestTime":"06-12 16:08:21","open":34.16,"high":35.4,"low":33.04,"amount":98865427,"amplitude":0.07028,"askPrice":34.9,"askSize":24100,"bidPrice":34.88,"bidSize":1700,"shortable":3,"etf":0,"ttmEps":-4.270376068643968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":7,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":33.58,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.0749041510654245,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2642287999","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642287999?lang=zh_cn&edition=full","pubTime":"2026-06-11 21:31","pubTimestamp":1781184682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月11日，受托人就2022年受限制股份单位计划目的于场内购买合共11万股现有股份以在归属后满足受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","AAPG","BK1574","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426730","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642426730?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:54","pubTimestamp":1781096082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月10日，受托人就2022年受限制股份单位计划目的于场内购买合共19万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4139","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169106576","title":"亚盛医药-B更新5月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1169106576","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169106576?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:21","pubTimestamp":1780575698,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年6月4日发布截至2026年5月31日止的股份变动月报表。公告显示，公司法定股本未发生变化，仍为500,000,000股普通股，面值每股US$0.0001，注册股本总额为US$50,000。公司当月库存股数量保持为0股。截至5月底，公司已发行股本总数增至373,555,768股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。上述月报表由公司秘书梁凯恩签字。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937177","title":"国泰海通证券：首予亚盛医药(06855)“增持”评级 目标价59.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937177","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640937177?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:58","pubTimestamp":1780304322,"startTime":"0","endTime":"0","summary":"2025年，公司商业化成果显著，实现总收益5.74亿元，不考虑武田付款同比增长90%，其中，奥雷巴替尼实现收入4.35亿元，利沙托克拉实现7085万元，合计5.06亿元。2025年末现金余额为24.7亿元，现金储备稳健，可以支撑到2027年。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["161027","EWH","02611","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982786","title":"【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，\"星光计划\"品种潜力初显","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982786","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640982786?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:40","pubTimestamp":1780278000,"startTime":"0","endTime":"0","summary":"此次快速口头报告的研究进展初步展现了APG-115在儿童相关实体瘤患者中的抗肿瘤活性和安全性。此次在ASCO 展示的数据证实，APG-115 单药及联合利沙托克拉展现出良好耐受性与显著抗肿瘤活性，尤其是CR 病例令人鼓舞。此次在ASCO展示的研究为APG-115治疗儿童实体瘤患者的数据首次亮相，初步展现的疗效和耐受性令人鼓舞。值得一提的是，APG-115此前已获CDE纳入'星光计划'，拟开发用于多种儿童实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1923622291.USD","BK4129","BK1161","06855","LU2125909759.SGD","BK4139","AAPG","LU2125909916.SGD","APG","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176445150","title":"异动解读｜亚盛医药-B盘中上涨6.35%，摘B里程碑叠加ASCO年会催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1176445150","media":"行情直击","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176445150?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:49","pubTimestamp":1780026583,"startTime":"0","endTime":"0","summary":"5月29日，亚盛医药-B盘中上涨6.35%，报39.86港元/股，成交额4217.63万港元。截至5月27日，公司市值约149.6亿港元，核心产品耐立克和利生妥收益超过5亿港元门槛。同时，ASCO年会于5月29日正式开幕，公司六项临床研究入选，其中三项获快速口头报告，涉及奥雷巴替尼、利沙托克拉及alrizomadlin三大重点品种。双重催化叠加生物科技板块整体回暖，信达生物涨10.29%、康方生物涨7.16%，带动公司股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639645908","title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2639645908","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639645908?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:23","pubTimestamp":1780025014,"startTime":"0","endTime":"0","summary":"财报显示，2025年，亚盛医药实现营业收入5.74亿元，且截至目前市值已超过百亿港元。而耐立克和利生妥两大十亿美元分子相继获批上市并在终端市场实现快速放量，便是亚盛医药能够顺利达成18A“摘B”里程碑的重要原因。智通财经APP了解到，亚盛医药今年六项重磅研究成果入选2026年ASCO年会。以上无疑都将成为亚盛医药年内的重要催化。近年来已有10数家18A企业顺利“摘B”，并在“摘B”后实现了可观的估值增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1161","BK4139","BK1574","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638992766","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638992766","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638992766?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:58","pubTimestamp":1779976713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月28日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK4139","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185669566","title":"异动解读｜亚盛医药-B盘中下跌6.24%，报37.58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185669566","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185669566?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:32","pubTimestamp":1779953535,"startTime":"0","endTime":"0","summary":"5月28日，亚盛医药-B盘中下跌6.24%，报37.58港元/股，成交额1.04亿港元。亚盛医药-B所在的生物科技行业整体承压，个股中，信达生物跌4.62%，康方生物跌4.34%，百济神州跌2.71%，三生制药跌7.23%，派格生物医药-B持平。亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司，核心产品包括耐立克（奥雷巴替尼）及Lisaftoclax（APG-2575），主要用于治疗CML、AML、CLL及MDS等血液肿瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651100","title":"亚盛医药获香港联交所批准从股票代码中移除\"B\"，6月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651100","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638651100?lang=zh_cn&edition=full","pubTime":"2026-05-28 11:06","pubTimestamp":1779937560,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年5月28日 /美通社/ --致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，因公司已符合香港联交所上市规则第8.05条的市值/收益要求，日前已获得香港联交所批准，将于2026年6月1日起正式将\"B\"标记从股票代码中移除。亚盛医药于2019年10月28日通过18A规则在香港联交所主板挂牌上市，后陆续纳入深港通和沪港通股票名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1161","BK1574","AAPG","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638081685","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买合共10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638081685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638081685?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:58","pubTimestamp":1779890296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月27日，受托人就2022年受限制股份单位计划目的于场内购买合共10万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","AAPG","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501850","title":"亚盛医药-B(06855)：中英文简称将不再加上标记“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638501850?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:31","pubTimestamp":1779877916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，由于相关规则不适用，公司的中英文简称自2026年6月1日起将不再加上标记“B”。公司的股份将以新英文股份简称“ASCENTAGE”及中文股份简称“亚盛医药”在联交所买卖。公司的股份代号维持不变，仍为“6855”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AAPG","BK4139","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363327","title":"亚盛医药-B(06855)：于2026年美国临床肿瘤学会年上公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637363327?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:46","pubTimestamp":1779407170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司六项入选2026年美国临床肿瘤学会年会的临床研究的摘要已于ASCO官网公布。本届ASCO年会将于2026年5月29日至2026年6月2日在芝加哥伊利诺伊州McCormick会议中心以线上线下结合的形式举办。该方案安全性可控，在儿童相关实体瘤中初步展现抗肿瘤活性，值得进一步研究。主要终点均为24周的主要分子学反应率。研究计划纳入约440例患者，在18个国家126个中心开展，目前正在招募中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","BK1574","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134177422","title":"异动解读｜亚盛医药盘中上涨7.32%，股东大会释放积极信号叠加指南纳入利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134177422","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134177422?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:05","pubTimestamp":1779329125,"startTime":"0","endTime":"0","summary":"5月21日，亚盛医药-B盘中上涨7.32%，报41.8港元/股，成交额5379.54万港元。消息面上，公司5月20日召开股东大会，管理层释放多重积极信号：明确核心产品APG-2575将立足自主商业化、不对外出售，已在寻找美国首席商务官；强调与武田的合作\"没有问题\"；并表示MDS适应症为最高优先级临床项目，计划明年下半年申请快速通道资格。此外，公司Bcl-2抑制剂利沙托克拉近日获纳入CSCO两项诊疗指南，在CLL/SLL、AML及MDS领域获权威推荐。多重利好共振推动股价反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","IE00B543WZ88.USD","BK1600","SG9999014674.SGD","06978","BK1583","IE00BPRC5H50.USD","LU0348767384.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348825331.USD","LU0417516902.SGD","02162","BK1574","02268","BK1191","LU1969619763.USD","LU2476274308.USD","159992","BK1593","LU0561508036.HKD","09939","LU0634319403.HKD","01672","BK1587","LU0348783233.USD","BK1515","LU0348827113.USD","BK1141","LU2328871848.SGD","LU2778985437.USD","LU2476274720.SGD","09926","LU1720050803.USD","LU2399975544.HKD","09995","LU0348735423.USD","LU0348784397.USD","06855","LU1961090484.USD","LU1794554557.SGD","LU2488822045.USD","LU0417516738.SGD","BK1161","LU0348766576.USD","159938","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163156926","title":"亚盛医药-B发布4月股份变动月报表，股本小幅增长10,058股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163156926","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163156926?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:43","pubTimestamp":1778164980,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年5月7日发布2026年4月股份变动月报表。公告显示，该公司截至2026年4月30日的法定/注册股本维持500,000,000股普通股，面值每股0.0001美元，对应注册股本共计50,000美元，未产生任何增减变动。公告披露，4月末已发行股份总数为373,334,750股，较3月底增加10,058股，库存股份数量保持为0股。截至4月底，亚盛医药-B股本结构整体保持相对稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121412043","title":"亚盛医药-B授予董事股份购回授权，规模达已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121412043","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121412043?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:11","pubTimestamp":1777414276,"startTime":"0","endTime":"0","summary":"亚盛医药-B在最新公告中披露，董事会已向股东大会提呈普通决议案，拟授予董事购回股份的一般授权，最多可回购相当于于批准日已发行股份总数10%的股份。据公告，截至公布前，公司已发行约3.73亿股，所涉回购规模最多约为3733.35万股。股东大会拟于2026年5月20日上午召开，会上将就回购授权进行表决。同时，为确保股东投票权的登记安排，股份过户登记将于2026年5月15日至2026年5月20日期间暂停办理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药-B授予董事股份购回授权，规模达已发行股本10%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140767462","title":"亚盛医药-B2025年业绩：收入回落至5.74亿元 研发投入加码致亏损显著扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1140767462","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140767462?lang=zh_cn&edition=full","pubTime":"2026-04-28 07:19","pubTimestamp":1777331996,"startTime":"0","endTime":"0","summary":"亚盛医药-B在2025年度实现收入5.74亿元人民币，较上年同期的9.81亿元明显下滑，研发投入则从9.47亿元增加至11.37亿元，推动全年亏损大幅上升至12.43亿元。管理层在年报中披露，公司核心业务仍聚焦于创新药物的研发与商业化，尤其是针对肿瘤领域的多条在研管线。公司在收入方面主要来自创新药物相关业务，但与去年相比出现明显回落；毛利约5.25亿元，销售成本上升至约4,894万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亚盛医药-B2025年业绩：收入回落至5.74亿元 研发投入加码致亏损显著扩大","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353293","title":"亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630353293?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4560","LU1162221912.USD","IE00B3PB1722.GBP","SG9999015986.USD","LU1244550577.SGD","LU1066053197.SGD","LU1066051811.HKD","LU1267930813.SGD","LU0234570918.USD","LU2237443465.HKD","IE00B42XCP33.USD","IE000M9KFDE8.USD","BK4579","LU2237443895.HKD","CSCL","LU1778281490.HKD","LU2102340556.USD","LU2286300806.USD","LU0868494708.USD","LU1883839398.USD","SG9999002224.SGD","BK4020","LU0942090050.USD","LU0823417653.USD","LU1674673691.USD","SG9999001424.SGD","LU1032955483.USD","LU0889566641.SGD","LU2247934214.USD","LU2237443622.USD","BK4585","IE00BSNM7G36.USD","IE00BVYPNV92.GBP","LU1571399168.USD","AAPG","LU0203347892.USD","LU0348723411.USD","06855","SG9999015945.SGD","BK4533","BK4588","BK1161","BK1574","CSCO","CSCS","LU0203345920.USD","LU1059921491.USD","LU1066051498.USD","LU0234572021.USD","LU1221951129.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","LU0196878994.USD","BK1589","01477","06990","06855","LU2097828474.EUR","LU2097828631.EUR","01801","02637","159992","BK1191","BK1515","01672","BK1161","LU2242644610.SGD","LU2328871848.SGD","LU2097828557.USD","09969","LU2097828805.USD","LU2488822045.USD","LU0502904849.HKD","HK0000165453.HKD","LU0455707207.USD","BK1574","BK1583","LU1969619763.USD","06978"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":-0.1438},{"period":"3month","weight":-0.2336},{"period":"6month","weight":-0.411},{"period":"1year","weight":-0.4443},{"period":"ytd","weight":-0.3321}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.714286,"avgChangeRate":0.098263},{"month":5,"riseRate":0.428571,"avgChangeRate":0.029409},{"month":6,"riseRate":0.714286,"avgChangeRate":0.246544},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.077026},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药","nameEN":"ASCENTAGE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,06855,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}